Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TTX-siMYC
- Development stage
- Preclinical
- Lead developer
- TransCode Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TTX-siMYC is an investigational therapeutic agent initially developed by TransCode Therapeutics. It is currently in the preclinical stage of development. The drug appears to be designed as a targeted therapy, likely utilizing small interfering RNA (siRNA) technology to silence the MYC proto-oncogene protein, which plays a critical role in cancer cell proliferation and survival. While detailed mechanism-of-action data specific to TTX-siMYC are not available in the provided sources, its name and developer’s focus suggest it is intended for oncology indications where MYC overexpression drives disease progression[1].
02
Targets
MYC (MYC proto-oncogene protein)
Beyond the preview
Go deeper on TTX-siMYC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TTX-siMYC.